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For decades the brain was considered an immunologically privileged site (1).
More recently, it has been realized that T cell-mediated allograft rejection and
other immune responses can take place within the brain (2-5). The unusually
low expression of MHC class I molecules in this organ (6, 7) is particularly
interesting in relation to recent findings where a T cell-independent but NK
cell-dependent defense, directed selectively against cells with reduced or defi-
cient expression of MHC class I molecules, has been suggested (8-11). We have
asked whether such a defense, possibly discriminating self from "no self," is
allowed to work in the brain. The rejection potential against H-2-deficient
tumor variants could not be detected in the brain, and our results suggest a
selective difference between T cell- and NK cell-dependent immunity extracra-
nially and intracranially.
Material and Methods
BriefDefinitive Report
Animals.
￿
All inbred mouse strains used in this study were bred and maintained at the
Dept. of Tumor Biology, Karolinska Institute.
Tumor Cell Lines.
￿
RBL-5 is a Rauscher virus-induced T cell lymphoma of C57BL/6
origin. The selection and subsequent phenotypic analysis of the RBL-5 H-2-deficient
variants have been described in detail elsewhere (9). All tumor cell lines used were
routinely passaged as ascites lines in H-2 identical or syngeneic F,-hybrid mice, preirra-
diated (400 rad) 24 h before tumor inoculation to avoid immunoselection. The following
nomenclature of the tumor cell lines is used in this study; RMA for the mutagenized but
not anti-H-2 selected RBL-5 lymphoma line. RMA-S and RMB-Sfor the two independently
mutagenized and anti-H-2 selected sublines. These lines have previously (9-11) been
called RMA H-2sel and RMB-S H-2 sel.
Tumor Growth Experiments.
￿
Data from the two independently selected H-2-deficient
lines were similar and were pooled in Table I. The different doses of ascitic tumor cells
were inoculated in 4-8-wk-old animals, three to six mice per group, usually littermates or
otherwise age matched within 2 wk in several independent experiments, and the subse-
quent data were pooled. Mice inoculated intracerebrally or intravenously were observed
daily after inoculation and were kept until they died in the initial experiments. In
subsequent studies, the mice were killed and autopsied when physiological or neurological
signs indicated that they would have died within 24 h because of the tumor burden. Mice
This investigation was supported by U.S. Public Health Service grant 5 RO1 CA-25250-06 and 1
RO1 CA-44882-01 awarded by the National Cancer Institute, and by grants from the Swedish
Cancer Society and the Swedish Society for Medicine. Address correspondence to Hans G. Ljunggren,
Dept. of Tumor Biology, Karolinska Institutet, Box 60 400, S-104 01 Stockholm, Sweden.
730
￿
J. Exp. MED. © The Rockefeller University Press - 0022-1007/88/02/730/06 $2.00
Volume 167
￿
February 1988 730-735LJUNGGREN ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
731
inoculated in the brain died from intracerebral lymphoma, intravenous inoculated mice
developed generalized lymphoma with massive infiltration of liver and lungs. Mice
inoculated subcutaneously or intraperitoneally were observed at least twice weekly. For
intracerebral inoculation, tumor cells were inoculated in a 10-j1 volume into the right
hemisphere with a microinjector (100-til type; Hamilton Co., Reno, NV) and a Yaoi
needle. Surgical thymectomy was performed on 3-4-wk-old anesthesized animals. 3 wk
later, the thymectomized mice (Thx) and control littermates (Thx-sham) received 735
rad whole body irradiation and were reconstituted by 5-15 X 106 i.v. inoculation of
syngeneic fetal liver cells. Immunized mice were prepared by three subcutaneous inocu-
lations with 10' preirradiated (10,000 rad) RMA H-2+ tumor cells with 1-wk intervals.
FRCS Analysis.
￿
For FACS analysis, tumors growing in the brain were removed under
sterile conditions and single cell suspensions were made. The tumor cells were subse-
quently put into tissue culture medium (RPMI + 5% FCS supplemented with antibiotics)
for ^-3-5 d and then analyzed on the FACS as described in reference 9. The mAbs were
the same as described previously (9).
Rapid Elimination Assay.
￿
The rapid elimination assay with 1251-IUdR-labeled cells was
performed as described (9).
Results and Discussion
Intracerebral Growth ofH-2+ and H-2- Tumor Grafts.
￿
The selectiveelimination
of subcutaneous or intravenous inoculated RBL-5 H-2- lymphoma cells (9, 11)
was markedly altered in the brain. When H-2+ and H-2- tumor cells were
inoculated into the brain, no difference in either tumor take (Table I) or survival
time (data not shown) was seen. In contrast, the H-2- cells required a 10'-10'-
fold higher dose, compared with the H-2+ cells, to induce >50% tumor take
after subcutaneous, intravenous, or intraperitoneal inoculation in control mice
(Table I). The changed pattern after intracranial inoculation was notjust due to
a different threshold dose for tumor inocula in general at this site. A wide range
of tumor doses were tested and there was never any difference in intracerebral
growth between the H-2+ and the H-2- cell lines.
Pathological examination of the H-2+ and H-2- tumor cells, growing in the
brain, showed no difference. Both tumor cell lines grew equally well at the site
of inoculation with extension along the needle track to the subarachnoidal space
(data not shown).
When the H-2+ and the H-2- cell lines were mixed in vitro in a 1:1 ratio and
inoculated intraperitoneally or subcutaneously in small doses in syngeneic mice,
only H-2+ tumor cells grew out and formed progressively growingascites or solid
tumors (12). When the same 1:1 mixture of H-2+ and H-2- tumor cells was
inoculated in the brain, the output tumor cell population consisted of both H-2+
and H-2- tumor cells, on average in a 1:1 ratio. This difference in tumor cell
outgrowth intracerebrally and intraperitoneally was seen even if the same animal
was inoculated at both locations simultaneously (Fig. 1) . This important control
indicated that the intracerebral inoculation per se had no systemic suppressive
effect on the host resistance against H-2- cells; the H-2- cells were always
eliminated selectively from the mixture at the extracranial sites.
No Rapid Elimination ofH-2- Cells in the Brain.
￿
The difference in extracranial
tumor growth between the H-2+ and H-2- tumor cells was previously attributed
to a rapid elimination mechanism taking place within 24 h after inoculation of
radiolabeled cells (9). In light of the results presented above, it could then be732
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TABLE I
Tumor Growth after Intracerebral, Subcutaneous, Intraperitoneal, and Intravenous
Inoculation ofRBL-5 H-2' and H-2- Tumor Cells
x
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FIGURE 1.
￿
FACS analysis of RBL-5 H-2' and H-2-
tumor cells indirectly stained with mabs against H-2Kb
and H-2Db. (a-c) The H-2' RMA wild-type line; (a)
nonspecific background staining with secondary anti-
body alone; (b) expression ofcell surface H-2antigens
after serial passage in 400 rad-irradiated animals; (c)
expression of cell surface H-2 antigens after progres-
sive growth in the brain. (df) The RMA-S H-2-
variant; (d) nonspecific background staining; (e)
expression of cell surface H-2 antigens after serial
passage in 400 rad-irradiated animals; (f) after pro-
gressive growth in the brain. (g-i) Three representa-
tive curves of cell suspensions from intracerebrally
growing tumors where the H-2' and H-2- line were
mixed in a 1 :1 ratio before Intracerebral inoculation.
In most experiments the progressively growing Intra-
cerebral tumor consisted of both tumor cell pheno-
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types (H-2' and H-2-) in equal amounts as illustrated
in g. In some mice one of the tumor cell populations
dominated as illustrated in h and i. The two cell surface phenotypes were equally often over
represented (data not shown). (j) An ascites tumor from one representative mouse inoculated
intraperitoneally with a 1 :1 mixture of H-2' and H-2- cells. The intraperitoneal rapidly growing
ascites cell line consists ofonly H-2' tumor cells. (k andl) Intracerebral andintraperitoneal inoculation
ofa 1 :1 mixture of H-2' and H-2-tumor cells in the same mouse; (k) intracerebrally, both the H-2'
andthe H-2- cellsgrew equally well (l) intraperitoneally, only H-2' cells grew. In all these experiments
10' cells were inoculated in normal syngeneic C57BL/6 mice. A logarithmic scale for fluorescence
was used to visualize the H-2-deficient (H-2-) tumor cell line.
predicted that this rapid elimination should not take place in the brain. To test
this, we inoculated radiolabeled H-2+ and H-2- cells intracerebrally, subcutane-
ously in the hind leg, and intravenously in normal syngeneic mice. No difference
in rapid elimination was seen between H-2+ and H-2- tumor cells in the brain
24 h after grafting of radiolabeled cells. In contrast, intravenously inoculated
control mice showed an up to 100-fold difference in clearance between H-2+
and H-2- tumor cells, with the most efficient elimination of H-2- cells in the
lungs, followed by the liver and the spleen (reference 9, Fig. 2). There was also
a more than fivefold difference in elimination between the H-2+ and the H-2-
tumor cells after subcutaneous inoculation (Fig. 2) .
Mice
Inoc-
ula-
tion
dose
Number of
Intracerebral
H-2' H-2-
mice with tumor growth/total number of mice
Subcutaneous Intraperitoneal
H-2' H-2- H-2' H-2-
inoculated
Intravenous
H-2' H-2-
C57BL/6 10' 0/5 0/5 - - - - - -
102 0/8 0/8 4/14 0/9 12/12 1/11 11/19 0/13
10' 10/12 12/12 11/14 1/27 11/12 0/14 9/11 0/13
10' 10/10 11/11 36/36 3/59 4/4 4/13 9/10 2/14
108 7/7 14/14 27/27 8/36 10/10 5/16 9/10 7/10
108 - - 8/8 12/12 5/5 4/5 10/10 10/10
A/Sn 10' 1/8 7/8
A/Sn Thx 10' 6/6 -
A/Sn Thx-sham 10' 0/4 3/4
CBA 10' 1/4 7/8
C57BL/6 H-2' im- 10' 0/4 4/4
munizedSOJ
y 20 .
IO I O
a
u S
z
u
z
LJUNGGREN ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
733
INTRACEREBRAL SUBCUTANEOUS
INOCULATION
J.
a
a a a
S01
20.
S .
2 .
INOCULATION
c
10
S
2
I
03
02
a
005
002
001
INTRAVENEOUS
INOCULATION
a
￿
a a
LUNG LIVER SPLEEN
z
FIGURE 2.
￿
Survival of '2sI-IUdR-labeled H-2' (RMA) and two H-2" (RMA-S and RMB-S)
RBL-5 tumor cells in syngeneic C57BL/6 mice 24 h after intracerebral, subcutaneous, or
intravenous inoculation. Theamount of radioactivity remainingin the head of intracerebrally
inoculated animals, in thehindlegof subcutaneously inoculated animals, and in the lung, liver
and spleen of intravenously inoculated animals indicates the amount of survivingtumor cells.
The results were pooled from four independent experiments with intracerebral inoculation,
seven independent experiments with subcutaneous inoculation, and two independent experi-
ments with intravenous inoculation, three to eight mice in each group, usually littermates or
otherwise age matched within 2 wk. Figure shows arithmetic mean and SD on a log scale.
Demonstration of Graft Rejection Against H-2+ Cells in the Brain.
￿
The present
data, demonstrating a selective acceptance of H-2- cells in the brain, are not in
conflict with previous evidence for immune reactions in the central nervous
system (CNS) (2-5, 13). In the same experimental system as above we could
confirm classical T cell-mediated rejections in the brain. When 104 H-2' cells
were inoculated intracerebrally they grew out in all normal syngeneic mice,
whereas most allogeneic or syngeneic preimmunized mice (immunized with the
RBL-5 H-2+ tumor) rejected them . If allogeneic mice were thymectomized,
irradiated, and reconstituted before intracerebral inoculation of H-2' cells, no
rejection was seen . This indicated that the rejection of H-2' cells in the brain
was T cell dependent (Table 1). The observation that the H-2- cells grew even
in allogeneic or preimmunized mice was consistent with the known importance
of MHC class I molecules in allogeneic (H-2-specific) and syngeneic (H-2-re-
stricted) immune responses (14).
Conclusions.
￿
The selective rejection of MHC class I-deficient cells extracra-
nially was previously shown to be dependent on NK cells (9-11). Furtherin vitro
analysis has suggested that NK cells distinguish between H-2+ and H-2- cells in
this system at a postbinding stage of the effector-target interaction (12) . Our
data suggest that mechanisms might have evolved to prevent rejection of MHC-
deficient cells in the brain, either by suppression of effector cell activity or
migration into the brain.
In tumor biology, the present findings may contribute knowledge to the
particular patterns of metastasis observed in relation to the CNS. Several leuke-
mias and solid tumors can spread and grow intracerebrally, while primary brain
tumors seldom metastasize extracranially.73 4
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From a more general immunological point of view, it is important to identify
the cells that can contribute to tissue damage during immune responses in the
CNS (5, 15). The rapid NK responses during viral infections could cause an
unnecessarily large irreversible damage of the nervous tissues and the brain in
particular. This activity might thus be locally prevented in favor of slower and
milder mechanisms for virus clearance (13).
In transplantation immunology, the present data are relevant to a peculiar
type of rejection seen against hematopoietic grafts. In addition to the conven-
tional T cell-mediated responses, allogeneic grafts as well as semisyngeneic
(parental into F, grafts) are often rapidly rejected by a thymus-independent
radioresistant mechanism (16, 17). It has been hypothesized that this surveillance
system might be directed against cells with a partial or complete absence of H-2
self markers of the host (8, 10). If these types of rejections are mediated by the
same NK-dependent system that rapidly rejects H-2- grafts extracranially, one
would expect them to be turned off in the brain. There are indications that this
may be the case (18).
The absence or suppression of the host defense against MHC class I deficient
cells in the brain could also be relevant for the rapidly growing interest in the
grafting of normal, neuronal, or other cellular components into the brain.
Summary
H-2-deficient (H-2-) tumor variants were accepted equally well compared with
H-2+ wild-type cells in the brain of syngeneic mice, while the H-2- cells were
selectively eliminated when inoculated extracranially. This indicates a specific
absence or suppression of the defense against MHC class I-deficient cells in the
brain, suggested to be mediated by NK cells. In contrast, T cell-mediated
immune reactions could clearly be detected in the brain under the same experi-
mental conditions . This was shown in control experiments where H-2+ tumor
cells were rejected from the brain of preimmunized or allogeneic mice. The
present findings may be important for the understanding of neurotropic virus
infections, immunology and immunotherapy of brain tumors, as well as for the
growing interest in tissue grafting within the central nervous system .
We thank Dr. Claes Ohlen for stimulating discussions.
Receivedfor publication 10 August 1987 and in revisedform 26 October 1987.
References
1. Baker, C. F., and R. E. Billingham . 1977. immunologically privileged sites. Adv.
Immunology 25 :1 .
2. Wikstrand, C. J., and D. D. Bigner. 1980. Immunobiologic aspects of the brain and
human gliomas. Am. J. Pathol. 98:517.
3. Darling, J. L., N. R. Hoyle, and D. G. T. Thomas. 1981 . Self and non-self in the
brain. Immunol. Today. 2:166.
4. Aarli, J. A. 1983. The immune system and the nervous system . J. Neurol. 229:137 .
5. Wekerle, H., C. Linington, H. Lassmann, and R. Meyermann. 1986. Cellular immune
reactivity within the CNS. Trends Neurosci. 9:271 .LJUNGGREN ET AL.
￿
BRIEF DEFINITIVE REPORT
￿
73 5
6. Williams, K., D. Hart, J. Fabre, and P. Morris. 1980. Distribution and quantitation
of HLA-A,B,C and DR (Ia) antigens on human kidney and other tissues. Transplan-
tation (Baltimore). 29:274.
7. Lampson, L. A., and W . F. Hickey. 1986. Monoclonal antibody analysis of MHC
expression in human brain biopsies: tissues ranging from "histologically normal" to
that showing different levels of glial tumor involvement. J. Immunol. 136:4054 .
8 . Karre, K. 1985. Role of target histocompatibility antigens in regulation of natural
killer activity: a reevaluation and a hypothesis. In Mechanisms of Cytotoxicity by NK
Cells. R. B. Herberman and D. M. Callewaert, editors. Academic Press, New York.
81-91 .
9. Ljunggren, H. G., and K. Karre. 1985. Host resistance directed selectively against
H-2-deficient lymphoma variants. Analysis of the mechanism.J. Exp. Med. 162:1745.
10. Karre, K., H. G. Ljunggren, G. Piontek, and Kiessling. 1986. Selective rejection of
H-2-deficient lymphoma variants suggests alternative immune defense strategy. Na-
ture (Lond.). 319:675.
11 . Ljunggren, H. G., and K . Karre. 1986. Experimental strategies and interpretations
in the analysis of changes in MHC gene expression during tumor progression. J.
Immunogenet. (Oxf.). 13:141 .
12. Ljunggren, H. G., C. Ohlen, P. H6glund, T. Yamasaki, G . Klein, and K. Karre.
1988 . Afferent and efferent cellular interactions in natural resistance directed against
MHC class I deficient tumor grafts. J. Immunol. In Press.
13. Oldstone, M. B ., P. Blount, P. J. Southern, and P. W. Lampert. 1986. Cytoimmu-
notherapy for persistent virus infection reveals a unique clearance pattern from the
central nervous system . Nature (Loud.). 321 :239.
14 . Doherty, P., B. Knowels, and P. I. Wettstein. 1984. Immunological surveillance of
tumors in the context of major histocompatibility complex restriction of T cell
function. Adv. Cancer Res. 42:1 .
15 . Allan, J. E., and P. C. Doherty. 1986. Natural killer cells contribute to inflammation
but do not appear to be essential for the induction of clinical lymphocytic chorio-
meningitis. Scand. J. Immunol. 24:153.
16. Cudkowicz, G., and M. Bennet. 1971 . Peculiar immunobiology of bone marrow
allografts. II Rejection of parental grafts by resistant F, hybrid mice . J. Exp. Med.
134:1513.
17. Carlson, G. A., D. Melnychuk, and M. J. Meeker. 1980. H-2 associated resistance to
leukemia transplantation: natural killing in vivo. Int. J. Cancer. 25:111 .
18. Circolo, A., R. Bianchi, B. Nardelli, P . Rivosecchi-Merletti, and E. Bonmassar. 1982.
Mouse brain: an immunologically privileged site for natural resistance against lym-
phoma cells. J. Immunol. 128 :556 .